Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update DOI Creative Commons
Masatoshi Kudo, Yusuke Kawamura, Kiyoshi Hasegawa

et al.

Liver Cancer, Journal Year: 2021, Volume and Issue: 10(3), P. 181 - 223

Published: Jan. 1, 2021

The Clinical Practice Manual for Hepatocellular Carcinoma was published based on evidence confirmed by the Evidence-based Guidelines along with consensus opinion among a Japan Society of Hepatology (JSH) expert panel hepatocellular carcinoma (HCC). Since JSH are original articles extremely high levels evidence, opinions HCC management in clinical practice or newly developed treatments not included. However, manual incorporates literature data, opinion, and real-world currently conducted to facilitate its use clinicians. Alongside each revision Guidelines, we issued an update manual, first edition 2007, second 2010, third 2015, fourth 2020, which includes 2017 Guideline. This article is excerpt from focusing pathology, diagnosis, treatment HCC. It designed as practical different latest version Guidelines. written JSH, emphasis statements recommendations proposed panel. In this article, included practices that relatively common Japanese experts field, although all their associated level but these likely be incorporated into guidelines future. To write coauthors institutions drafted content then critically reviewed other’s work. revised Board Directors Planning Public Relations Committee before publication confirm recommendations. presented report represent measures actually being at highest-level centers Japan. We hope provides insight actual situation Japan, thereby affecting global pattern

Language: Английский

Cancer statistics, 2023 DOI Open Access

Rebecca L. Siegel,

Kimberly D. Miller, Nikita Sandeep Wagle

et al.

CA A Cancer Journal for Clinicians, Journal Year: 2023, Volume and Issue: 73(1), P. 17 - 48

Published: Jan. 1, 2023

Each year, the American Cancer Society estimates numbers of new cancer cases and deaths in United States compiles most recent data on population-based occurrence outcomes using incidence collected by central registries mortality National Center for Health Statistics. In 2023, 1,958,310 609,820 are projected to occur States. increased prostate 3% annually from 2014 through 2019 after two decades decline, translating an additional 99,000 cases; otherwise, however, trends were more favorable men compared women. For example, lung women decreased at one half pace (1.1% vs. 2.6% annually) 2015 2019, breast uterine corpus cancers continued increase, as did liver melanoma, both which stabilized aged 50 years older declined younger men. However, a 65% drop cervical during 2012 among their early 20s, first cohort receive human papillomavirus vaccine, foreshadows steep reductions burden papillomavirus-associated cancers, majority Despite pandemic, contrast with other leading causes death, death rate decline 2020 (by 1.5%), contributing 33% overall reduction since 1991 estimated 3.8 million averted. This progress increasingly reflects advances treatment, particularly evident rapid declines (approximately 2% 2016 2020) leukemia, kidney cancer, despite stable/increasing incidence, accelerated cancer. summary, although rates continue future may be attenuated rising breast, prostate, also happen have largest racial disparities mortality.

Language: Английский

Citations

12228
Hepatocellular carcinoma DOI Open Access
Josep M. Llovet, Robin Kate Kelley, Augusto Villanueva

et al.

Nature Reviews Disease Primers, Journal Year: 2021, Volume and Issue: 7(1)

Published: Jan. 21, 2021

Language: Английский

Citations

4516
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update DOI Open Access
María Reig, Alejandro Forner, Jordi Rimola

et al.

Journal of Hepatology, Journal Year: 2021, Volume and Issue: 76(3), P. 681 - 693

Published: Nov. 19, 2021

Language: Английский

Citations

2810
Hepatocellular carcinoma DOI

Arndt Vogel,

Tim Meyer, Gonzalo Sapisochín

et al.

The Lancet, Journal Year: 2022, Volume and Issue: 400(10360), P. 1345 - 1362

Published: Sept. 6, 2022

Language: Английский

Citations

1345
Immunotherapies for hepatocellular carcinoma DOI
Josep M. Llovet, Florian Castet, Mathias Heikenwälder

et al.

Nature Reviews Clinical Oncology, Journal Year: 2021, Volume and Issue: 19(3), P. 151 - 172

Published: Nov. 11, 2021

Language: Английский

Citations

1193
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade DOI Creative Commons
Golnaz Morad, Beth A. Helmink, Padmanee Sharma

et al.

Cell, Journal Year: 2021, Volume and Issue: 184(21), P. 5309 - 5337

Published: Oct. 1, 2021

Language: Английский

Citations

1083
PD-L1 as a biomarker of response to immune-checkpoint inhibitors DOI
Deborah B. Doroshow, Sheena Bhalla, Mary Beth Beasley

et al.

Nature Reviews Clinical Oncology, Journal Year: 2021, Volume and Issue: 18(6), P. 345 - 362

Published: Feb. 12, 2021

Language: Английский

Citations

1074
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma DOI Creative Commons
Ann‐Lii Cheng, Shukui Qin, Masafumi Ikeda

et al.

Journal of Hepatology, Journal Year: 2021, Volume and Issue: 76(4), P. 862 - 873

Published: Dec. 11, 2021

IMbrave150 demonstrated that atezolizumab plus bevacizumab led to significantly improved overall survival (OS) and progression-free (PFS) compared with sorafenib in patients unresectable hepatocellular carcinoma at the primary analysis (after a median 8.6 months of follow-up). We present updated data after 12 additional follow-up.Patients systemic treatment-naive, were randomized 2:1 receive 1,200 mg 15 mg/kg intravenously every 3 weeks or 400 orally twice daily this open-label, phase III study. Co-primary endpoints OS PFS by independently assessed RECIST 1.1 intention-to-treat population. Secondary efficacy included objective response rates exploratory subgroup analyses. This is post hoc safety.From March 15, 2018, January 30, 2019, 501 (intention-to-treat population) randomly allocated (n = 336) 165). On August 31, 2020, 15.6 (range, 0-28.6) follow-up, was 19.2 (95% CI 17.0-23.7) 13.4 11.4-16.9) (hazard ratio [HR] 0.66; 95% 0.52-0.85; descriptive p <0.001). The 6.9 5.7-8.6) 4.3 4.0-5.6) respective treatment groups (HR 0.65; 0.53-0.81; < 0.001). Treatment-related grade 3/4 adverse events occurred 143 (43%) 329 72 (46%) 156 safety-evaluable groups, treatment-related 5 6 (2%) 1 (<1%) patients.After longer maintained clinically meaningful benefits over had safety profile consistent analysis.NCT03434379.The showed greater than advanced carcinoma, but not yet mature. At done later, 5.8 sorafenib, severity side effects remained similar. These results confirm as first-line standard care for carcinoma.

Language: Английский

Citations

1041
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma DOI Creative Commons
Richard S. Finn, Masafumi Ikeda, Andrew X. Zhu

et al.

Journal of Clinical Oncology, Journal Year: 2020, Volume and Issue: 38(26), P. 2960 - 2970

Published: July 27, 2020

PURPOSE The immunomodulatory effect of lenvatinib (a multikinase inhibitor) on tumor microenvironments may contribute to antitumor activity when combined with programmed death receptor-1 (PD-1) signaling inhibitors in hepatocellular carcinoma (HCC). We report results from a phase Ib study plus pembrolizumab (an anti–PD-1 antibody) unresectable HCC (uHCC). PATIENTS AND METHODS In this open-label multicenter study, patients uHCC received (bodyweight ≥ 60 kg, 12 mg; < 8 mg) orally daily and 200 mg intravenously day 1 21-day cycle. included dose-limiting toxicity (DLT) an expansion (first-line patients). Primary objectives were safety/tolerability (DLT phase), objective response rate (ORR) duration (DOR) by modified RECIST (mRECIST) version 1.1 (v1.1) per independent imaging review (IIR; phase). RESULTS A total 104 enrolled. No DLTs reported (n = 6) the DLT phase; 100 (expansion n 2 phase) had no prior systemic therapy Barcelona Clinic Liver Cancer stage B 29) or C disease 71). At data cutoff, 37% remained treatment. Median follow-up was 10.6 months (95% CI, 9.2 11.5 months). Confirmed ORRs IIR 46.0% 36.0% 56.3%) mRECIST 26.6% 46.2%) v1.1. DORs 8.6 6.9 not estimable [NE]) 12.6 NE) progression-free survival 9.3 overall 22 months. Grade 3 treatment-related adverse events occurred 67% (grade 5, 3%) patients. new safety signals identified. CONCLUSION Lenvatinib has promising uHCC. Toxicities manageable, unexpected signals.

Language: Английский

Citations

1008
Liver cirrhosis DOI
Pere Ginés, Aleksander Krag, Juan G. Abraldeṣ

et al.

The Lancet, Journal Year: 2021, Volume and Issue: 398(10308), P. 1359 - 1376

Published: Sept. 17, 2021

Language: Английский

Citations

978